RxDoctor Payments Data

Susan Scheck

Nurse Practitioner · Warrenville, ILNPI 1831674480

Payments from drug & device makers

$2,918in general payments, 2019–2025

Across 102 payments — averaging $28.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Seagen Inc.$246
  • AstraZeneca$244
  • AbbVie$242
  • Lilly USA, LLC$214
  • Bristol Myers Squibb$187
  • Novartis$147
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$2,63090%
  • Education$28810%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,918 in reported general payments places this provider in the 90th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$26,574
Medicare patients
137
Services billed
347

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib42$871,294
RevlimidLenalidomide16$308,537
IbrancePalbociclib11$155,574
EliquisApixaban11$7,637
Exemestane18$3,875
Anastrozole92$1,522
Letrozole65$1,436
Tamoxifen Citrate38$692
Dexamethasone48$689
Acyclovir28$486
Gabapentin23$394
Hydroxyurea24$345
Prochlorperazine Maleate36$315
Ondansetron Hcl45$249
Lidocaine-PrilocaineLidocaine/Prilocaine24$240

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$16$871,29442 claims
Bristol Myers SquibbRevlimid$187$308,53716 claims
PfizerIbrance, Eliquis$60$163,21122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Warrenville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →